Our Approach

eFFECTOR is pioneering the field of Selective Translation Regulators (STRs)

Transcription is the copying of DNA sequences into mRNA, whereas translation is the subsequent utilization of mRNA sequences to direct protein synthesis. While the regulation of transcription is widely recognized, eFFECTOR is pioneering the field of Selective Translation Regulators (STRs).

DNA

mRNA

Proteins

Regulation of transcription

Transcription

eFFECTOR Proteins

Growth
Immune Activity
Inflammation
Stress Response

Regulation of translation

Translation

Unregulated
routine/majority

Regulated
potent/minority

"Housekeeping"
Proteins

eFFECTOR’s translation regulation targets are downstream of key signaling pathways and impact multiple complementary cancer growth and survival mechanisms.

The importance of translation regulation in disease is becoming increasingly recognized in the pharmaceutical industry, and we believe we are at the forefront of discovering novel approaches to cancer therapy focused on STRs. Utilizing our proprietary selective translation regulation technology platform, we have developed an understanding of genes that are translationally dysregulated in multiple tumor types and other diseases. This has enabled us to identify specific points of therapeutic intervention that may have a meaningful clinical effect.

Immune
Resistance

Tumor
Metabolism

Inflammation
Tumor
Promotion

Sustaining
Proliferation

Resisting
Cell Death

MNK

eIF4G

eIF4E

eIF4A

Signaling
Inputs

Translational
Regulation

PI3K

RAS

MYD88

Cancer
Drivers

Our programs target three distinct subunits of the translation initiation complex: MNK 1/2, eIF4A and eIF4E. Each of these subunits regulates distinct sets of cancer genes.

Key regulation points for potent biological processes
- Downstream from multiple oncogenes
- Upstream from key cancer driving processes
Terminal node in key signaling pathways limits resistance mechanisms

Each target regulates a distinct cancer gene set